LONG BEACH, CA - March 11, 2026 - PRESSADVANTAGE - Moment of Clarity has published a new educational resource detailing ...
Moment of Clarity has published a comprehensive new resource on its website addressing insurance coverage for transcranial ...
TMS is a well-established therapy for treatment-resistant depression. Large clinical studies show that it significantly reduces symptoms in 60 to 70% of patients, and 25 to 35% achieve remission. Most ...
Soterix Medical Inc., the global leader in non-invasive stimulation and integrated brain monitoring technologies, announced today clearance from the U.S. Food & Drug Administration (FDA) for the SPRY ...
TMS uses electromagnetic induction to stimulate neurons, similar to how a wireless charger transfers energy. The FDA has cleared TMS for Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder ...
Moment of Clarity has released a new educational resource providing a detailed examination of the “benefits and limitations of Transcranial Magnetic Stimulation (TMS) therapy“. The article, now ...
Published results have shown 87% clinical response to non-invasive Transcranial Magnetic Stimulation with neuroplastic medications.Clinical ...
CHEYENNE – Cheyenne Regional Medical Center is expanding access to behavioral health care with the addition of NeuroStar Transcranial Magnetic Stimulation therapy, recently cleared by the U.S. Food an ...